Head to Head Review: Endonovo Therapeutics (OTCMKTS:ENDV) and Outset Medical (NASDAQ:OM)

Endonovo Therapeutics (OTCMKTS:ENDVGet Free Report) and Outset Medical (NASDAQ:OMGet Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Volatility & Risk

Endonovo Therapeutics has a beta of -1.41, indicating that its share price is 241% less volatile than the S&P 500. Comparatively, Outset Medical has a beta of 1.99, indicating that its share price is 99% more volatile than the S&P 500.


This table compares Endonovo Therapeutics and Outset Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Endonovo Therapeutics -1,717.21% N/A -408.63%
Outset Medical -132.54% -102.50% -52.42%

Earnings & Valuation

This table compares Endonovo Therapeutics and Outset Medical’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Endonovo Therapeutics $140,000.00 5.95 -$18.48 million N/A N/A
Outset Medical $130.38 million 0.98 -$172.80 million ($3.50) -0.70

Endonovo Therapeutics has higher earnings, but lower revenue than Outset Medical.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Endonovo Therapeutics and Outset Medical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Endonovo Therapeutics 0 0 0 0 N/A
Outset Medical 1 2 3 0 2.33

Outset Medical has a consensus target price of $5.42, indicating a potential upside of 120.19%. Given Outset Medical’s higher probable upside, analysts clearly believe Outset Medical is more favorable than Endonovo Therapeutics.


Outset Medical beats Endonovo Therapeutics on 6 of the 9 factors compared between the two stocks.

About Endonovo Therapeutics

(Get Free Report)

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

About Outset Medical

(Get Free Report)

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Receive News & Ratings for Endonovo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endonovo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.